Biotech companies are paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. The field is booming with excitement, with pharma companies increasing investment into these pipelines in the race to successfully reverse hearing damage.

Returning as an in-person event to Boston, the 2^nd Inner Ear Disorders Therapeutics Summit will unite drug developers focusing on preventative and regenerative approaches targeting the inner ear.

Debate the clinical applicability of different modalities, including small molecule, stem cell and gene therapy; accurately monitor hearing loss progress, successfully identify new targets, optimize preclinical models, discuss combination strategies for drugs and devices and hear the latest clinical updates and novel translatable research of the inner ear.

Join over 100 drug developers from the likes of Otonomy, Sound Pharmaceuticals, Frequency Therapeutics, Astellas, Sensorion, Decibel Therapeutics and more at this 4-day disease-agnostic, modality-agnostic event designed specifically for industry-based experts in inner ear disorders to successfully translate their therapeutics into the clinic.

To know more visit: https://ter.li/1wvymk